Caliway to Current Outcomes of Section 2b CBL-514 Research for Subcutaneous Fats Discount at IMCAS 2025 in Paris By Investing.com

• Outcomes from the CBL-0204 Section 2b medical trial have been chosen to be offered at IMCAS, the premier world congress for aesthetic medication. The info might be highlighted on the 2025 Focus Session on Advances in Fats Discount Therapies and detailed on the Non-Surgical Physique Contouring Session via an oral presentation.
• The Section 2b outcomes of CBL-0204 spotlight the exceptional efficacy and security profile of CBL-514 for localized fats discount. Main and secondary endpoints had been met, making CBL-514 the primary injectable therapy doubtlessly meant for large-area fats discount. This trial was additionally the primary to undertake FDA-recommended endpoints, together with SCALE and MRI-based assessments, paving the way in which for a pivotal world Section 3 medical trial anticipated to start in 2025.

NEW TAIPEI CITY, December 18, 2024 /PRNewswire/ — Caliway Biopharmaceutical (Caliway) is happy to announce that the corporate will current outcomes from the Section 2b research of CBL-514 (Section 2b of CBL-0204) on 26^th IMCAS World Congress In Paris, France. CBL-514 is the primary injectable for large-area fats discount, with Section 2b research outcomes exhibiting greater than 80% of contributors handled with CBL-514 achieved at the least 1 stage of enchancment AFRS (stomach fats score scale).

Dr. Michael H. GoldPrincipal Investigator of Caliway’s Stomach Subcutaneous Fats Discount Scientific Trials, to Current Early Section 2b Outcomes of CBL-0204 at Non-Surgical Physique Contouring Session on February 1^st2025, to 3:00 p.m. (Central European Time, GMT+1 hour).

Presentation of the outcomes of the Caliway CBL-0204 research at IMCAS Data:

Session 1: IMCAS World Congress FOCUS 2025 session

• Fats Discount Therapies in 2025 “What’s New and What Works with EBDs and Injectables?
• Date/time: Thursday January 30, 2025 to to 11:54 p.m.
• Place: Room 402 – Degree 4, Palais des Congrés de Paris(2 Pl de la Pte Maillot, 75017 Paris, France)

Session 2: IMCAS World Congress 2025 | Non-surgical physique contouring

• A Novel Non-Surgical Fats Discount Therapy: A Section 2b Research Evaluating the Efficacy of CBL-514 Injection in Lowering Stomach Subcutaneous Fats
• Date/time: Saturday, February 1, 2025 has 3:00 p.m. (Central European Time, GMT+1 hour)
• Place: Room 401 – Degree 4, Palais des Congrés de Paris(2 Pl de la Pte Maillot, 75017 Paris, France)

For extra data on the session, please go to:

• https://www.imcas.com/en/attend/imcas-world-congress-2025/program/session/55933
• https://www.imcas.com/en/attend/imcas-world-congress-2025/program/session/56195#lectures

About IMCAS World Congress

IMCAS World Congress is a devoted medical aesthetics occasion that brings collectively greater than 18,700 healthcare and business professionals to supply a worldwide overview of the newest breakthroughs and improvements within the dermatology, cosmetic surgery and growing older scientific neighborhood. For extra data, please go to: https://www.imcas.com/en/attend/imcas-world-congress-2025

In regards to the CBL-514

CBL-514, a first-in-class small molecule drug, is a lipolysis injectable that may induce apoptosis and lipolysis of adipocytes to cut back subcutaneous adiposity in therapy areas with out inflicting unwanted side effects systematic research on the central nervous system, cardiovascular and respiratory methods. system. Caliway’s preclinical research confirmed that CBL-514 upregulates apoptosis mediators, caspase 3 and Bax/Bcl-2 ratio, after which induces adipocyte apoptosis in vivo and in vitro.

Caliway is investigating a number of indications for CBL-514, together with non-invasive discount of subcutaneous fats, Dercum’s illness and cellulite. Thus far, a complete of 520 topics have enrolled within the CBL-514 medical research. In keeping with 9 medical research carried out in three indications, CBL-514 demonstrated particular efficacy with a positive security profile. The worldwide pivotal section 3 research of non-surgical fats discount might be carried out in 2025.

About Caliway Biopharmaceutical

Caliway Biopharmaceutical (Caliway) is a clinical-stage biopharmaceutical firm targeted on the breakthrough discovery of novel small molecule medicine. Listed on the Taipei Inventory Change (TWSE-6919), Caliway goals to grow to be an revolutionary pharmaceutical chief within the subject of aesthetic medication and different ailments.

For extra data, please go to: https://www.caliway.com.tw/en/

Disclaimer

This text and associated data on this web site incorporates forward-looking statements. Ahead-looking data requires the Firm to make quite a few assumptions and is topic to inherent dangers, uncertainties and different components past the Firm’s management which can trigger precise outcomes, efficiency or achievements to be materially completely different. completely different from future outcomes, efficiency or achievements. or achievements expressed or implied by such forward-looking statements. The Firm assumes no obligation to well timed inform, replace or revise the knowledge on this web site ought to circumstances change.

CONTACT: information@caliway.com.tw